Statement: The total number of patients affected by adverse events in cohort 2 the primary trial is more than 1000.
Primary_evidence: Adverse Events 1:   Total: 379/1288 (29.43%)   Febrile neutropenia  84/1288 (6.52%)   Neutropenia  69/1288 (5.36%)   Leukopenia  8/1288 (0.62%)   Anaemia  1/1288 (0.08%)   Thrombocytopenia  4/1288 (0.31%)   Pancytopenia  1/1288 (0.08%)   Febrile bone marrow aplasia  1/1288 (0.08%)   Atrial fibrillation  4/1288 (0.31%)   Cardiac failure congestive  6/1288 (0.47%) Adverse Events 2:   Total: 250/1271 (19.67%)   Febrile neutropenia  59/1271 (4.64%)   Neutropenia  38/1271 (2.99%)   Leukopenia  1/1271 (0.08%)   Anaemia  3/1271 (0.24%)   Thrombocytopenia  0/1271 (0.00%)   Pancytopenia  1/1271 (0.08%)   Febrile bone marrow aplasia  0/1271 (0.00%)   Atrial fibrillation  2/1271 (0.16%)   Cardiac failure congestive  0/1271 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 15/148 (10.14%)   Febrile neutropenia 1/148 (0.68%)   Atrial fibrillation 2/148 (1.35%)   Abdominal pain 1/148 (0.68%)   Diarrhoea 1/148 (0.68%)   Pyrexia 2/148 (1.35%)   Cellulitis 1/148 (0.68%)   Device related infection 2/148 (1.35%)   Gastroenteritis viral 1/148 (0.68%)   Gastrointestinal infection 1/148 (0.68%)   Upper respiratory tract infection 1/148 (0.68%)